This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove) (TE-Prove)

This study has been completed.
Sponsor:
Collaborator:
Pharmaceutical Research Associates
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01242696
First received: November 16, 2010
Last updated: February 2, 2017
Last verified: February 2017
November 16, 2010
February 2, 2017
November 2010
March 2013   (Final data collection date for primary outcome measure)
Target Vessel failure [ Time Frame: 1 year ]
Overall and TAXUS Element stent related Target Vessel Failure (TVF) rate (cardiac death, myocardial infarction (MI) related to target vessel and target vessel re-intervention (TVR)) at 12 months post stent implantation
Same as current
Complete list of historical versions of study NCT01242696 on ClinicalTrials.gov Archive Site
  • Stent Thrombosis [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Stent Thrombosis (ST) rate using Academic Research Consortium (ARC) definition (definite/probable with no censoring for Target Lesion Reintervention, (TLR)).
  • MACE [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Overall and TAXUS Element stent-related Major Adverse Cardiac Events (MACE) rates (cardiac death, MI, TVR).
  • Cardiac Death or MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Overall and TAXUS Element stent-related cardiac death or MI rates
  • TVR [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Overall and TAXUS Element stent-related TVR rates
  • Cardiac Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Overall and TAXUS Element stent-related cardiac death rates
  • MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Overall and TAXUS Element stent-related MI rates
  • All Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    All Death rates
  • Non-Cardiac Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    Non-Cardiac Death rates
  • All Death or MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 3 years post index stent implantation ]
    All Death or MI rates
  • Stent Thrombosis [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Stent Thrombosis (ST) rate using Academic Research Consortium (ARC) definition (definite/probable with no censoring for Target Lesion Reintervention, (TLR)).
  • MACE [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Overall and TAXUS Element stent-related Major Adverse Cardiac Events (MACE) rates (cardiac death, MI, TVR).
  • Cardiac Death or MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Overall and TAXUS Element stent-related cardiac death or MI rates
  • TVR [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Overall and TAXUS Element stent-related TVR rates
  • Cardiac Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Overall and TAXUS Element stent-related cardiac death rates
  • MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Overall and TAXUS Element stent-related MI rates
  • All Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    All Death rates
  • Non-Cardiac Death [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    Non-Cardiac Death rates
  • All Death or MI [ Time Frame: 30 days, 6 months, 12 months and then annually through 5 years post index stent implantation ]
    All Death or MI rates
Not Provided
Not Provided
 
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS® Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice.
A prospective, open label, multi-center observational study with an all-comers enrollment approach of approximately 1000 subjects at up to 50 sites in Europe.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
Coronary Heart Disease
Procedure: Coronary artery stenting
Coronary artery stenting with drug eluting stents
Other Name: TAXUS Element
Coronary artery stenting
All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
Intervention: Procedure: Coronary artery stenting
Tamburino C, Capodanno D, Erglis A, Menown IB, Horváth IG, Moreno R, Gilbert TJ, Crowley JJ, Calabria P, Allocco DJ, Dawkins KD. One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). EuroIntervention. 2015 Mar;10(11):1261-6. doi: 10.4244/EIJY15M01_01.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1014
July 2015
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • According to Instructions For Use

Exclusion Criteria:

  • Contraindications according to Instructions for Use
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Germany,   Hungary,   Ireland,   Italy,   Latvia,   Poland,   Spain,   United Kingdom
 
 
NCT01242696
S2059
No
Not Provided
Plan to Share IPD: No
Plan Description: Primary endpoint data presented at TCT 2014.
Boston Scientific Corporation
Boston Scientific Corporation
Pharmaceutical Research Associates
Principal Investigator: Corrado Tamburino, Prof. Ospedale Ferrarotto, Via Citelli, 1, 95100 Catania, Italy
Study Director: Peter Maurer, PhD Boston Scientific Corporation
Boston Scientific Corporation
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP